549 Stereotactic Radiosurgery for Non-Functioning Pituitary Adenoma Recurrence With Low Dose 12 Gy

View at publisher Summarise with VIRAT
Authors: Gabriel Flores-Milan, Ali A. Mohamed, Ivo Peto, Keaton Piper, Jenna Marek, Davide M. Croci, Michael Yu, Rahul Suresh Mhaskar, Harry van Loveren, Siviero Agazzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: The existing literature presents varying opinions on the appropriate dosage of stereotactic radiosurgery (SRS) for the recurrence of nonfunctional pituitary adenomas (NPAr). While it is theorized that administering higher doses may reduce the likelihood of recurrence, there is a growing concern that such doses could compromise neurological function by damaging nearby structures. METHODS: An institutional review board-approved retrospective study was conducted for patients who underwent SRS for NPAr from 2006 to 2022. Collected information included demographics, treatment parameters, preoperative and postoperative neurologic and endocrinologic function, and postoperative hormone management. Patients treated with 12 Gy were compared to all other patients with a dosage range of 1/13 to 28/50.4. RESULTS: A total of 63 patients were included in the study, 23 of which were treated with 12 Gy and 40 treated with different doses of radiation. The average follow up was 21 and 34 months, respectively. No significant differences were found in gender, age, tumor volume, preoperative hormone replacement, endocrine function, diabetes insipidus, and cranial nerve (CN) deficit between groups (p = 0.117, p = 0.531, p = 0.482, p = 0.793, p = 0.439, p = 0.494, and p = 0.535, respectively). Additionally, no significant differences were found in postoperative hormone replacement, hormone replacement in 1 year, diabetes insipidus, CN deficit, CN deficit in 1 year, and recurrence post radiation (p = 0.603, p = 0.399, p = 0.652, p = 0.535, p = 0.214, and p = 0.701, respectively). CONCLUSIONS: SRS treatment of NPAr using a low dose of 12 Gy is as effective as higher radiation doses while minimizing the risk of functional neurological deficits and showed noninferiority to compared modalities.

Fields of Study & Subjects

Pituitary Gland Disorders and Treatments Meningioma and schwannoma management Neuroendocrine Tumor Research Advances

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
164–165
Publication date
26 March 2026
Language
EN